{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Raynaud&page=2",
    "query": {
      "condition": "Raynaud",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Raynaud&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:51:36.612Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03869008",
      "title": "Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Raynaud Phenomenon",
        "Primary Raynaud Phenomenon",
        "Raynaud Disease",
        "Raynaud Syndrome"
      ],
      "interventions": [
        {
          "name": "gammaCore Sapphire",
          "type": "DEVICE"
        },
        {
          "name": "Sham Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Toledo Health Science Campus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2019-04-30",
      "completion_date": "2020-02-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 1,
      "location_summary": "Toledo, Ohio",
      "locations": [
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03869008"
    },
    {
      "nct_id": "NCT03867097",
      "title": "Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo IV infusion",
          "type": "DRUG"
        },
        {
          "name": "Iloprost Injection, for intravenous use",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Civi Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2019-03-07",
      "completion_date": "2019-08-06",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867097"
    },
    {
      "nct_id": "NCT03941184",
      "title": "Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SCAD",
        "Addison Disease",
        "Ankylosing Spondylitis",
        "Antiphospholipid Antibody Syndrome",
        "Celiac Disease",
        "Crohn Disease",
        "Dermatomyositis",
        "Polymyositis",
        "Guillain-Barre Syndrome",
        "Hepatitis, Autoimmune",
        "Graves Disease",
        "Hashimoto Thyroiditis",
        "Multiple Sclerosis",
        "Myasthenia Gravis",
        "Pernicious Anemia",
        "Polymyalgia Rheumatica",
        "Primary Biliary Cirrhosis",
        "Psoriasis",
        "Rheumatoid Arthritis",
        "Systemic Sclerosis",
        "Sjögren Syndrome",
        "Systemic Lupus Erythematosus",
        "Takayasu Arteritis",
        "Type 1 Diabetes Mellitus",
        "Ulcerative Colitis",
        "Uveitis",
        "Vasculitis",
        "Vitiligo",
        "Raynaud"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 114,
      "start_date": "1995-01-01",
      "completion_date": "2020-11-10",
      "has_results": false,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03941184"
    },
    {
      "nct_id": "NCT04854850",
      "title": "Apollo Device for Fatigue in Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Fatigue",
        "Raynaud Phenomenon"
      ],
      "interventions": [
        {
          "name": "Apollo",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Robyn T. Domsic, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2020-07-07",
      "completion_date": "2023-03-15",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04854850"
    },
    {
      "nct_id": "NCT04915950",
      "title": "A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Temanogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-11-03",
      "completion_date": "2022-09-02",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04915950"
    },
    {
      "nct_id": "NCT04040322",
      "title": "Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo IV infusion",
          "type": "DRUG"
        },
        {
          "name": "Iloprost Injection, for intravenous use",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Civi Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2019-10-14",
      "completion_date": "2021-06-09",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04040322"
    },
    {
      "nct_id": "NCT01090492",
      "title": "PF-00489791 For The Treatment Of Raynaud's",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Disease",
        "Peripheral Vascular Disease"
      ],
      "interventions": [
        {
          "name": "PF-00489791",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 243,
      "start_date": "2010-08-04",
      "completion_date": "2011-05-31",
      "has_results": true,
      "last_update_posted_date": "2018-05-16",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 23,
      "location_summary": "Redwood City, California • Farmington, Connecticut • Washington D.C., District of Columbia + 19 more",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01090492"
    },
    {
      "nct_id": "NCT06675344",
      "title": "The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Sclerosis (SSc)"
      ],
      "interventions": [
        {
          "name": "Apollo Neuro Device",
          "type": "DEVICE"
        },
        {
          "name": "Sham device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Robyn T. Domsic, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2025-01-06",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 4,
      "location_summary": "New Orleans, Louisiana • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06675344"
    },
    {
      "nct_id": "NCT00577304",
      "title": "A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Raynaud's Disease",
        "Raynaud's Disease Secondary to Scleroderma",
        "Raynaud's Disease Secondary to Other Autoimmune Disease"
      ],
      "interventions": [
        {
          "name": "Nitroglycerin",
          "type": "DRUG"
        },
        {
          "name": "Topical AmphiMatrix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediQuest Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "15 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2007-12",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2010-02-05",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 17,
      "location_summary": "Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577304"
    },
    {
      "nct_id": "NCT02683408",
      "title": "Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Raynaud's Disease"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "diosmiplex",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Primus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 87,
      "start_date": "2016-02",
      "completion_date": "2017-07",
      "has_results": false,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-05-22T04:51:36.612Z",
      "location_count": 11,
      "location_summary": "Peoria, Arizona • Scottsdale, Arizona • Los Alamitos, California + 8 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02683408"
    }
  ]
}